Dr Amol Akhade
@SuyogCancer
Followers
8K
Following
35K
Media
2K
Statuses
9K
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists
Mumbai
Joined June 2019
Happy to share our article in lancet oncology about Accelerated pathway ( mis ) use in oncology drug approval and differential treatment given by pharma giants to LMIC , while withdrawing cancer drugs. Thank you @oncology_bg @SirohiBhawna for being with me for this efforts .
21
45
203
RT @medicalwatchBC: Hi friends, it's #LungCancer Wednesday. Here are Top Posts of the Week! 🎉🎉🎉. 1/ Our friend @suyogcancer on a trial of….
0
4
0
“Face-Off in EGFR NSCLC: Aumolertinib vs Osimertinib, ACROSS-2 vs FLAURA2”.Any predictions ? Who will win ? .@brunolarvol @medicalwatchBC @dr_yakupergun @Alfdoc2 @StephenVLiu #WCLC2025.
linkedin.com
Aumolertinib, Osimertinib, and the Face off ACROSS-2 Vs FLAURA2 One of the most intriguing parallels at WCLC 2025 is between ACROSS-2, the phase III trial of aumolertinib + chemotherapy, and the...
3
8
28
So NICE is not So " NICE " to. " Laura " . To be fair , Laura was much better conducted trial ( as compared to ADAURA) and this decision probably has more to do with economics ( of the country) than Science alone . What do u think ? 🤔.
BTOG can confirm that NICE has released draft guidance as follows:. Osimertinib should not be used for the maintenance treatment of locally advanced (stage 3) unresectable non-small cell lung cancer (NSCLC) in adults when the tumours have epidermal growth factor receptor (EGFR)
3
3
16
HARMONi-A and the Curious Case of OS: From “Negative Drift” to a Positive Surprise. One of the most anticipated stories at #WCLC25 will be the HARMONi-A trial of ivonescimab (PD-1/VEGF bispecific) in EGFR-mutated, TKI-resistant NSCLC. Why? Because the overall survival (OS) curve
4
13
52
Finally MonarchE got OS after 7 years . It will be intresting to see magnitude of Benifit. Looking forward to the data . @OncoAlert @brunolarvol @dr_yakupergun @medicalwatchBC
2
24
70
RT @NiuSanford: @SuyogCancer @brunolarvol @oncodaily @medicalwatchBC @OncBrothers Lovely read! Yin & Yang.
0
1
0
RT @OncBrothers: @SuyogCancer @brunolarvol @oncodaily @medicalwatchBC Absolutely love this! Connecting dots with our beliefs, culture, and….
0
1
0
Lord Ganesha, Janus, and JAK2: Guardians of Thresholds. Do Read My New Post on Substack. 🙂👇 @brunolarvol @oncodaily @medicalwatchBC @OncBrothers.
7
3
23
RT @oncodaily: @SuyogCancer We would like to inform you that your post has been published on Thank you for sharing….
oncodaily.com
Amol Akhade: Junk Food and Cancer Risk / Amol Akhade, cancer, OncoDaily, Oncology
0
1
0
RT @NiuSanford: ctDNA in CRC with @KristenCiombor! . Here we discuss:.-recent MRD trials (DYNAMIC III, etc).-endpoints.-current NCCN recs.-….
0
24
0
Lot of people ask me about Junk Food and cancer risk . Hope this will answer those questions 🙂 #CancerAwareness #healthylifestyle
1
7
40
RT @OncBrothers: Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings,….
0
14
0
RT @Vikalp_Prithvi: August 29: Watch 'What If I Tell You' followed by Q&A with @teenaakaur at @PrithviTheatre. The film is about the direct….
0
3
0
RT @Supreeth_medonc: Our perspective on Burnout among oncologists in India, published on @IJMPOofficial Thanks to Dr Amol Akhade @SuyogCanc….
0
3
0
RT @chadinabhan: The “CHALLENGE” trial presented at @ASCO #ASCO25 & pub in @NEJM made a lot of noise - exercise improves OS?.The PI him….
0
6
0
RT @oncodaily: @PTarantinoMD @SuyogCancer We would like to inform you that your post has been published on OncoDaily. Thank you for sharing….
oncodaily.com
Paolo Tarantino: The Challenges Faced by Letters to the Editor / Amol Akhade, cancer, OncoDaily, Oncology, Paolo Tarantino
0
1
0
RT @dr_yakupergun: A brilliant post on the importance of Letters to the Editor and the indifference of journals — inspired by @Suyocancer's….
0
11
0
RT @OncBrothers: This is the algorithm for reference during our discussion with @HosseinBorghaei during our discussion on #SmallCellLungCan….
0
66
0